132 related articles for article (PubMed ID: 22145270)
1. The use of acetyl cholinesterase inhibitors and memantine in nursing home residents.
Gorus E; Van Puyvelde K; Corremans V; Mets T
Acta Clin Belg; 2011; 66(5):361-6. PubMed ID: 22145270
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
Blaszczyk AT; Mang BH; Garza H; Mathys M
Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Beier MT
Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
[TBL] [Abstract][Full Text] [Related]
5. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Gauthier S; Molinuevo JL
Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study.
Havreng-Théry C; Oquendo B; Zolnowski-Kolp V; Krolak-Salmon P; Bertin-Hugault F; Lafuente-Lafuente C; Belmin J
Alzheimers Res Ther; 2024 May; 16(1):117. PubMed ID: 38812028
[TBL] [Abstract][Full Text] [Related]
7. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
Pfeil AM; Kressig RW; Szucs TD
Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
[TBL] [Abstract][Full Text] [Related]
9. Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease.
Fillit H; Hofbauer RK; Setyawan J; Tourkodimitris S; Fridman M; Pejović V; Miller ML; Erder MH; Lyketsos C
J Am Med Dir Assoc; 2010 Nov; 11(9):636-644. PubMed ID: 21029998
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
[TBL] [Abstract][Full Text] [Related]
11. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of dementia and use of anti-dementia drugs in nursing homes].
Engedal K
Tidsskr Nor Laegeforen; 2005 May; 125(9):1188-90. PubMed ID: 15880157
[TBL] [Abstract][Full Text] [Related]
13. Use of memantine for the treatment of dementia.
Lo D; Grossberg GT
Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
[No Abstract] [Full Text] [Related]
15. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
Lachaine J; Beauchemin C; Legault M; Bineau S
Can J Psychiatry; 2011 Oct; 56(10):596-604. PubMed ID: 22014692
[TBL] [Abstract][Full Text] [Related]
16. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T
Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252
[No Abstract] [Full Text] [Related]
17. Antipsychotic drug use among nursing home residents taking rivastigmine.
Narayanan S; Beusterien KM; Thomas SK; Musher J; Strunk B
J Am Med Dir Assoc; 2006 Jan; 7(1):12-6. PubMed ID: 16413429
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment of dementia.
Schwarz S; Froelich L; Burns A
Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's treatment in nursing homes: room for improvement.
Bright-Long L
J Am Med Dir Assoc; 2006 Feb; 7(2):90-5. PubMed ID: 16461250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
